Angiotensin 1-7 (Ang-(1-7)) is a major active component of the renin-angiotensin system (RAS), produced from cleavage of Ang II by angiotensin-converting-enzyme type 2 (ACE2). Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity.
Registration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
Synonyms/Alias | Angiotensin (1-7);51833-78-4;angiotensin 1-7;ASP-ARG-VAL-TYR-ILE-HIS-PRO;TXA127;Angiotensin i (1-7);angiotensin-(1-7);Angiotensin II (1-7) heptapeptide;angiotensin II (1-7);8-Des-phe-angiotensin II;Ang-(1-7);TXA-127;Human angiotensin-(1-7);1-7-Human angiotensin II;Sh-heptapeptide-13;Bf-angiotensin 1-7;TXA 127;IJ3FUK8MOF;ang 1-7;MFCD00153513;39386-80-6;Angiotensin peptide (1-7);5-ile-angiotensin-(1-7);Human angiotensin ii (1-7);CHEBI:55438;Ile(5)-angiotensin II (1-7);Angiotensin II, 5-L-isoleucine-8-de-L-phenylalanine-;Angiotensin I/II (1-7) trifluoroacetate salt;(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid;Angiotensin (1-7) xTFA salt;L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-proline;L-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-proline;(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-hydroxy-4-oxobutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(3H-imidazol-4-yl)propanoyl]pyrrolidine-2-carboxylic acid;angiotensin-I (1-7);UNII-IJ3FUK8MOF;Angiotensin, Canine, Rat;Ang I (1-7);Angiotensin II, des-phe(8)-;(2S)-1-((2S)-2-(((2S,3S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-amino-4-hydroxy-4-oxobutanoyl)amino)-5-(diaminomethylideneamino)pentanoyl)amino)-3-methylbutanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)-3-methylpentanoyl)amino)-3-(3H-imidazol-4-yl)propanoyl)pyrrolidine-2-carboxylic acid;Ang-1-7 acetate;Angiotensin(1-7);DRVYIHP;Angiotensin II, des-phenylalanine(8)-;Angiotensin i/ii(1-7);Talfirastide (USAN/INN);GTPL582;Ang(1-7);GTPL5578;Therapeutic Angiotensin-(1-7);ANGIOTENSIN 1-7 ACETATE;CHEMBL3545347;SCHEMBL15926158;SCHEMBL25354851;BDBM85556;PVHLMTREZMEJCG-GDTLVBQBSA-N;[125I]ang-(1-7);GLXC-15146;ANGIOTENSIN 1-7 [WHO-DD];EX-A7295;SH-HEPTAPEPTIDE-13 [INCI];TXA127; Ang-(1-7);AKOS024456667;AKOS040759110;CS-3413;DB11720;Angiotensin (1-7) acetate salt hydrate;Angiotensin II, 8-de-L-phenylalanine-;NCGC00167219-01;AS-76407;DA-70861;FA108515;HY-12403;NS00073118;1-7-ANGIOTENSIN II, 5-L-ISOLEUCINE-;D12942;F85068;[125I]angiotensin-(1-7) (human, mouse, rat);BRD-K36040345-001-01-1;BRD-K36040345-001-02-9;Q27074464;(2S)-1-[(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-AMINO-3-CARBOXYPROPANAMIDO]-5-CARBAMIMIDAMIDOPENTANAMIDO]-3-METHYLBUTANAMIDO]-3-(4-HYDROXYPHENYL)PROPANAMIDO]-3-METHYLPENTANAMIDO]-3-(1H-IMIDAZOL-4-YL)PROPANOYL]PYRROLIDINE-2-CARBOXYLIC ACID;(S)-1-((6S,9S,12S,15S,18S)-18-((1H-imidazol-4-yl)methyl)-1-amino-6-((S)-2-amino-3-carboxypropanamido)-15-sec-butyl-12-(4-hydroxybenzyl)-1-imino-9-isopropyl-7,10,13,16-tetraoxo-2,8,11,14,17-pentaazanonadecane)pyrrolidine-2-carboxylic acid; |
M.F/Formula | C41H62N12O11 |
M.W/Mr. | 899 |
Sequence | One Letter Code:DRVYIHP Three Letter Code:H-Asp-Arg-Val-Tyr-Ile-His-Pro-OH |
Biological Activity | Endogenous peptide fragment. Induces vasorelaxation through release of NO and prostaglandins, perhaps through activation of a non-AT1, non-AT2 receptor, Mas. Counteracts the vasoconstrictive and proliferative effects of angiotensin II and stimulates vasopressin (anti-diuretic hormone) release in vivo. |
Source# | Synthetic |
Length | 7 |
Long-term Storage Conditions | Soluble to 1 mg/ml in water |
Shipping Condition | Room temperature in continental US; may vary elsewhere. |
InChI | InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1 |
InChI Key | PVHLMTREZMEJCG-GDTLVBQBSA-N |
2. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum
4. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.